Business Wire

Americhem Unveils 2024 Sustainability Report Highlighting Major Accomplishments

Share

Report Showcases Company’s Commitment to Environmental Responsibility, Highlights Future Ambitions

Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, proudly announces the release of its 2024 Sustainability Report. This comprehensive report, titled Embracing Our Tomorrow, highlights Americhem’s unwavering commitment to environmental and social responsibility, providing an in-depth look at the company’s efforts across the entire value chain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205637181/en/

Lauren Lutikoff, Americhem Global Sustainability Leader (Photo: Business Wire)

Following the recent award of the Silver EcoVadis Medal, which places Americhem among the top 15% of companies assessed by EcoVadis—a globally recognized platform that rates businesses’ sustainability in various categories including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. Americhem’s sustainability report showcases the company’s major accomplishments and outlines future ambitions, including:

Americhem 2030 Plan: Over the past few years, Americhem has established baseline performance metrics and set targets within the business for each key pillar, aligning with the UN Sustainable Development Goals and Americhem’s vision for sustainability. The plan outlines the company’s dedication to advancing operations, developing sustainable solutions, and empowering employees, all while contributing to the communities in which it operates.

Americhem Decarbonization Strategy: The report reveals a robust decarbonization strategy focused on renewable energy, waste handling, and resource conservation projects at Americhem’s facilities. Other actions include increasing collaborative efforts with suppliers and customers to reduce greenhouse gas emissions.

“Meeting the sustainability goals of our customers requires the same mindset—embracing change while meeting the high-quality standards that consumers demand. Embarking on our sustainability journey is more than just a commitment; it’s a pledge for the future. Our mission is to lead with integrity, innovate responsibly, and inspire progress,” said John Richard, CEO at Americhem.

Major Accomplishments Built on Three Critical Pillars

Americhem’s sustainable framework is built on three critical pillars: People, Process, and Product. In 2024, Americhem rolled out programs and launched new products that contributed to these pillars, including:

People: Americhem’s commitment to world-class safety is demonstrated through its “Next Level Safety” campaign. The company has significantly surpassed industry benchmarks, with a Total Recordable Incident Rate (TRIR) 22% below the industry average.

Process: Americhem announced it is now sourcing 100% electricity through a local renewable energy program for its World Headquarters location. This transition is estimated to avoid approximately 750 metric tons of CO2 emissions annually1, equivalent to the carbon sequestered by 875 acres of U.S. forests in one year2.

Product: Americhem continues to lead in innovation with new product offerings such as the EcoLube™ line of PFAS-free internally lubricated compounds, addressing industry challenges around proposed PFAS regulations and promoting environmental responsibility.

Lauren Lutikoff, Americhem’s Global Sustainability Leader, said, “Americhem’s initiatives are aligned with the company’s commitment to innovation, while continually advancing environmental responsibility and product safety.”

“In today’s world, operating sustainably is no longer a choice, but a necessity. At Americhem, we recognize that sustainability is fundamental to our future and the well-being of our planet. This report is not just an accounting of our accomplishments, but rather a path for continued improvement and a testament of our dedication to a better tomorrow,” added Lutikoff.

To read Americhem’s sustainability report, visit www.americhem.com/pages/sustainability.

About Americhem

Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.

1Calculation based on City of Cuyahoga Falls’ Utility Department Emissions Factor Rating for 2022 and Americhem Global Headquarters’ annual electricity consumption data.

2Calculation based on the EPA’s Greenhouse Gas Equivalency Calculator (https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator#results)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205637181/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release

Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital

Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release

This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye